ENGNenGene Therapeutics Inc.同业对比
enGene Therapeutics Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENGN本股 | $99M#6 | 0.6x#1 | 0.4x#1 | — | — | -112.7%#12 | — | -50.9%#7 | — | — | -78.7%#10 | — |
| NMRA | $115M#1 | — | 2.6x#9 | — | — | -2.8%#8 | — | 532.2%#2 | -594.0%#4 | — | -79.5%#11 | — |
| OTLK | $112M#2 | — | — | 79.5x#6 | — | 17.2%#6 | -4744.3%#6 | — | -12.8%#2 | — | -64.6%#8 | — |
| VYGR | $111M#3 | — | 0.7x#2 | 2.7x#5 | -49.5%#5 | -84.2%#11 | -326.6%#5 | -77.6%#9 | — | — | -60.8%#7 | — |
| ARMP | $109M#4 | — | — | — | — | -818.8%#14 | — | — | — | — | -39.1%#4 | 0.1%#1 |
| BDTX | $103M#5 | — | 1.1x#5 | 1.5x#4 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | -54.4%#6 | — |
| ATRA | $85M#7 | — | — | 0.7x#2 | -6.3%#3 | 138.3%#1 | 29.7%#1 | — | — | — | -40.2%#5 | — |
| TNYA | $84M#8 | — | 1.2x#6 | — | — | 18.5%#5 | — | -130.5%#10 | — | — | -73.7%#9 | — |
| VXRT | $80M#9 | 2.0x#2 | 1.0x#3 | 0.3x#1 | 726.7%#1 | 124.4%#3 | 7.6%#3 | 0.0%#3 | 22.5%#1 | — | -24.0%#2 | — |
| CSBR | $68M#10 | — | 17.5x#10 | 1.1x#3 | 4.4%#2 | -125.0%#13 | -1.9%#4 | -0.0%#4 | — | — | -27.6%#3 | — |
| CRDF | $66M#11 | — | 2.5x#8 | 112.0x#7 | -13.2%#4 | -0.9%#7 | -8256.3%#7 | -0.2%#5 | — | — | — | — |
| CGTX | $65M#12 | — | 2.0x#7 | — | — | 30.9%#4 | — | -71.1%#8 | — | — | — | — |
| GRMLW | $57M#13 | — | 1.0x#4 | — | — | -71.6%#10 | — | -18.2%#6 | -14.6%#3 | — | — | — |
| INKT | $55M#14 | — | — | — | — | -15.9%#9 | — | — | — | — | -23.4%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议